Fanconi syndrome induced by zoledronic acid: Two case reports

These cases highlight the importance of early recognition and close monitoring of renal tubular function in patients receiving ZA. Screening for FS, including urinalysis, blood gas analysis, and serum electrolytes, should be considered within the first month of therapy and repeated regularly thereafter. Clinicians should maintain high vigilance for FS, especially when ZA is used concurrently with other nephrotoxic agents such as adefovir.